Superiority of Mi-ADMS to DMSA as parenteral treatment for decreasing mercury (203Hg) body burden in rats.
The efficiency of meso-2,3-dimercaptosuccinic acid (DMSA) and the monoisoamyl ester of meso-2,3-dimercaptosuccinic acid (Mi-ADMS) in decreasing 203Hg retention was evaluated in rats in relation to age and time of treatment. The experiments were performed on six-week- and seven-day-old Wistar rats, which received 203Hg by intraperitoneal administration. The chelators DMSA or Mi-ADMS were also administered intraperitoneally, twice, on two consecutive days, in doses of 0.25 mmol/kg body weight as early (0.5 and 24 h) or delayed treatment (24 and 48 h, or 48 and 72 h) after 203Hg administration. The retention of 203Hg was determined in the carcass, liver, kidneys and brain six days after administration using gamma scintillation counters (double crystal, well type). In all experimental conditions, regardless of the animals' age and time of chelation therapy, Mi-ADMS was found to be superior to DMSA in reducing the body burden of 203Hg in whole body and organs. Mi-ADMS therefore seems to be a very promising chelator in the treatment of mercury poisoning.
Kostial
K
K
Institute for Medical Research and Occupational Health, University of Zagreb, Croatia.
Blanusa
M
M
Piasek
M
M
Simonović
I
I
Jones
M M
MM
Singh
P K
PK
D000818:Animals; D001822:Body Burden; D015913:Chelation Therapy; D008628:Mercury; D008630:Mercury Poisoning / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D004113:Succimer / Q000031:analogs & derivatives / Q000627:therapeutic use*
D004113:Succimer; D008628:Mercury